1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Global Osteoporosis Drugs Market, By Drug Class, By Osteoporosis Disease Type, By Route of Administration, By Gender, By Distribution Channel, By Region, Forecast & Opportunities, 2026

Global Osteoporosis Drugs Market, By Drug Class, By Osteoporosis Disease Type, By Route of Administration, By Gender, By Distribution Channel, By Region, Forecast & Opportunities, 2026

  • March 2021
  • 112 pages
  • ID: 6036627
  • Format: PDF
  • TechSci Research

Summary

Table of Contents

Global Osteoporosis Drugs Market, By Drug Class (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, and Others), By Osteoporosis Disease Type (Primary Osteoporosis, Secondary Osteoporosis), By Route of Administration (Oral, Injectable, and Others), By Gender (Female, Male), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, Forecast & Opportunities, 2026

The global osteoporosis drugs market stood at USD13.36 billion in 2020 and is projected to grow at a CAGR of 6.83% to cross USD20.17 billion by 2026. The increase in the prevalence of osteoporosis in postmenopausal women and rising awareness among the public about osteoporosis care are some key factors propelling the market growth. Moreover, growing investment in R&D activities for the development of advanced new drug classes and a wide range of pipeline drugs for approval in clinical trials are expected to provide lucrative growth opportunities for osteoporosis drug manufacturers.
Osteoporosis drugs are used to treat osteoporosis, which is a bone disease.Osteoporosis may occur due to lower than normal peak bone mass and greater than normal bone mass loss.

Other reasons behind this disease include a number of diseases or treatments such as anorexia, surgical removal of the ovaries, hyperthyroidism, alcoholism, and kidney disease.Moreover, lifestyle associated factors such as smoking and alcohol abuse can also promote osteoporosis.

Hence these factors are leading to a spike in demand for osteoporosis drugs around the world.
The global osteoporosis drugs market can be segmented based on disease type, drug class, route of administration, gender, distribution channel and region.Based on the route of administration, the market can be segmented into oral, injectable, and others.

Among them, the injectable segment is expected to witness high CAGR during the forecast period owing to the growing need for drugs that exhibit improved bioavailability rapid mode of action.
Regionally, North America dominated the global osteoporosis drugs market in 2020 owing to the rising prevalence of osteoporosis and easy availability of osteoporosis drugs in the region. However, Asia Pacific is expected to witness the fastest growth through 2026 owing to growing awareness about the benefits of osteoporosis drugs and thriving life science industry.
Major companies operating in the global osteoporosis drugs market include F. Hoffmann-La Roche Ltd, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Novartis International AG, GlaxoSmithKline Plc, Merck & Co. Inc., Amgen, Inc., Allergan plc, Eli Lilly and Company, Radius Health, Inc., Sun Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited, Sanofi S.A., Abiogen Pharma S.p.A., Merrion Pharmaceuticals Plc., among others. The market players are taking up growth strategies like collaborations, new product launches, partnership & acquisitions.

Years considered for this report:

Historical Years: 2016-2019
Base Year: 2020
Estimated Year: 2021
Forecast Period: 2022-2026

Objective of the Study:

• To analyze the historical growth in the market size of the global osteoporosis drugs market from 2016 to 2019.
• To estimate and forecast the market size of the global osteoporosis drugs market from 2021 to 2026 and growth rate until 2026.
• To forecast global osteoporosis drugs market based on drug class, route of administration, company and regional distribution.
• To identify drivers and challenges for global osteoporosis drugs market.
• To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in global osteoporosis drugs market.
• To identify and analyze the profile of leading players operating in the global osteoporosis drugs market.
The analyst performed both primary as well as exhaustive secondary research for this study.Initially, the analyst sourced a list of osteoporosis drug manufacturers across the globe.

Subsequently, the analyst conducted primary research surveys with the identified companies.While interviewing, the respondents were also enquired about their competitors.

Through this technique, the analyst could include the companies which could not be identified due to the limitations of secondary research.
The analyst calculated global osteoporosis drugs market size using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. The analyst sourced these values from the industry experts and company representatives and externally validated through analysing historical data of these product types and applications for getting an appropriate, overall market size.

Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used by the analyst.

Key Target Audience:

• Osteoporosis drugs manufacturers, companies/partners and other stakeholders
• Government bodies such as regulating authorities and policy makers
• Organizations, industry associations, forums and alliances related to osteoporosis drugs
• Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as osteoporosis drug manufacturing companies, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global osteoporosis drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
• Global Osteoporosis Drugs Market, By Osteoporosis Disease Type:
o Primary Osteoporosis
o Secondary Osteoporosis
• Global Osteoporosis Drugs Market, By Drug Class:
o Bisphosphonates
o Selective Estrogen Inhibitors Modulator (SERM)
o Parathyroid Hormone Therapy
o Calcitonin
o Rank Ligand Inhibitors
o Others
• Global Osteoporosis Drugs Market, By Route of Administration:
o Oral
o Injectable
o Others
• Global Osteoporosis Drugs Market, By Gender:
o Male
o Female
• Global Osteoporosis Drugs Market, By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Global Osteoporosis Drugs Market, By Region:
o North America
- United States
- Mexico
- Canada
o Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
o Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Singapore
o South America
- Brazil
- Argentina
- Colombia
o Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global osteoporosis drugs market.

Available Customizations:

With the given market data, we offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).
Profit Margin Analysis
• Profit margin analysis in case of direct and indirect sales channel.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Osteoarthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • $ 2500
  • April 2022
  • 413 pages

Osteoarthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis - Drugs ...

  • World
  • Musculoskeletal Disorder
  • Arthritis
  • Industry analysis

ref:plp2021

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on